改善心血管结局：动脉粥样硬化个性化治疗时代
Improving Cardiovascular Outcomes: The Era of Personalized Therapy in Atherosclerosis.
作者信息
Kabłak-Ziembicka Anna
机构信息
Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Św. Anny 12, 31-008 Kraków, Poland.
Noninvasive Cardiovascular Laboratory, The John Paul II Hospital, Prądnicka 80, 31-202 Kraków, Poland.
出版信息
J Clin Med. 2022 May 30;11(11):3077. doi: 10.3390/jcm11113077.
Abstract
Data from the European Society of Cardiology report that cardiovascular disease (CVD) is responsible for app [...].
摘要
欧洲心脏病学会的数据显示，心血管疾病（CVD）是造成约[...]的原因。 （注：原文“app [...]”表述不完整，翻译可能会存在一定局限性）
相似文献
1
Improving Cardiovascular Outcomes: The Era of Personalized Therapy in Atherosclerosis.
J Clin Med. 2022 May 30;11(11):3077. doi: 10.3390/jcm11113077.
2
Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines.
Circ Cardiovasc Qual Outcomes. 2021 Sep;14(9):e007183. doi: 10.1161/CIRCOUTCOMES.120.007183. Epub 2021 Sep 21.
3
European Society of Cardiology: cardiovascular disease statistics 2021: Executive Summary.
Eur Heart J Qual Care Clin Outcomes. 2022 Jun 6;8(4):377-382. doi: 10.1093/ehjqcco/qcac014.
4
European Society of Cardiology: Cardiovascular Disease Statistics 2017.
Eur Heart J. 2018 Feb 14;39(7):508-579. doi: 10.1093/eurheartj/ehx628.
5
Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology.
Eur Heart J. 2006 Apr;27(8):994-1005. doi: 10.1093/eurheartj/ehi819. Epub 2006 Mar 7.
6
Nutrition and physical activity recommendations from the United States and European cardiovascular guidelines: a comparative review.
Curr Opin Cardiol. 2020 Sep;35(5):508-516. doi: 10.1097/HCO.0000000000000763.
7
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.
8
Personalized Management of Cardiovascular Disorders.
Med Princ Pract. 2017;26(5):399-414. doi: 10.1159/000481403. Epub 2017 Sep 11.
9
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
J Am Heart Assoc. 2017 Nov 9;6(11):e006537. doi: 10.1161/JAHA.117.006537.
10
Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement.
Atherosclerosis. 2021 Dec;338:55-63. doi: 10.1016/j.atherosclerosis.2021.09.022. Epub 2021 Nov 8.
引用本文的文献
1
A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients-A Review PART II-Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory.
J Clin Med. 2024 Mar 5;13(5):1508. doi: 10.3390/jcm13051508.
2
A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients-A Review: Part I-Epidemiology, Risk Factors, and Atherosclerosis-Related Diversities in Elderly Patients.
J Clin Med. 2024 Mar 3;13(5):1471. doi: 10.3390/jcm13051471.
本文引用的文献
1
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
BMJ. 2022 May 4;377:e069116. doi: 10.1136/bmj-2021-069116.
2
The Maintained Glycemic Target Goal and Renal Function Are Associated with Cardiovascular and Renal Outcomes in Diabetic Patients Following Stent-Supported Angioplasty for Renovascular Atherosclerotic Disease.
J Pers Med. 2022 Mar 28;12(4):537. doi: 10.3390/jpm12040537.
3
Overview of FDA Circulatory System Devices Panel virtual meeting on TriGUARD 3 cerebral embolic protection.
Catheter Cardiovasc Interv. 2022 May;99(6):1789-1795. doi: 10.1002/ccd.30098. Epub 2022 Jan 27.
4
Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for Cardiovascular Disease in 2017 and Trends and Risk Analysis From 1990 to 2017 Using the Global Burden of Disease Study and Implications for Prevention.
Front Public Health. 2021 Oct 29;9:559751. doi: 10.3389/fpubh.2021.559751. eCollection 2021.
5
Clinical Significance of Carotid Intima-Media Complex and Carotid Plaque Assessment by Ultrasound for the Prediction of Adverse Cardiovascular Events in Primary and Secondary Care Patients.
J Clin Med. 2021 Oct 9;10(20):4628. doi: 10.3390/jcm10204628.
6
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
Cardiovasc Res. 2022 Jul 27;118(10):2231-2252. doi: 10.1093/cvr/cvab271.
7
Fibrin Clot Properties in Atherosclerotic Vascular Disease: From Pathophysiology to Clinical Outcomes.
J Clin Med. 2021 Jul 5;10(13):2999. doi: 10.3390/jcm10132999.
8
Targeting the Autonomic Nervous System for Risk Stratification, Outcome Prediction and Neuromodulation in Ischemic Stroke.
Int J Mol Sci. 2021 Feb 26;22(5):2357. doi: 10.3390/ijms22052357.
9
Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease.
J Cardiovasc Dev Dis. 2021 Jan 27;8(2):11. doi: 10.3390/jcdd8020011.
10
Observed and Expected Survival in Men and Women After Suffering a STEMI.
J Clin Med. 2020 Apr 19;9(4):1174. doi: 10.3390/jcm9041174.
Zotero 插件